Working… Menu
Trial record 1 of 1 for:    ABP 938
Previous Study | Return to List | Next Study

A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04270747
Recruitment Status : Recruiting
First Posted : February 17, 2020
Last Update Posted : September 9, 2021
Information provided by (Responsible Party):

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : June 17, 2022
Estimated Study Completion Date : December 8, 2022